News

2025-04 – Q1 2025 Reporting
  • Draft report SER150 CL-009 was received and will be discussed with the Australian contract organisation and the Serodus biostatistician consultant.
  • In March 2025 the company launched a Private Placement with a following Subsequent Offering. The commitment amounted to NOK 20,1 million.

Read more here

2025-03 – 2024 Annual Report

Serodus AS – Publishes 2024 Annual Report

Download it here

2024-10 – Q3 2024 Reporting
  • Unblinding of the database after SER150 CL-009 was delayed.
  • Calculation of SER150 effect on kidney function compared to placebo is consequently also delayed.

Read more here

2024-08 – Q2 2024 Reporting
  • Contacts to banks for assisting Serodus in selling Serodus AS, the pipeline or the individual assets was initiated.
  • Database for SER150 CL-009 is expected to be unblinded late August or early September.

Read more here

2024-05 – 2023 Annual Report

Serodus ASA – Publishes 2023 Annual Report

Download it here